Central serous chorioretinopathy management: current evidence and future directions in pharmacologic and phototherapeutic interventions – a literature review Review article

Article Sidebar

PDF


Published: Mar 24, 2026
DOI: https://doi.org/10.24292/01.OT.200326
Keywords:
central serous chorioretinopathy, photodynamic therapy, subthreshold micropulse laser, mineralocorticoid antagonist

Main Article Content

Krzysztof Marcinkowski
Students’ Scientific Society, Department of Ophthalmology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
https://orcid.org/0009-0002-5759-7285
Maciej Michalik
Students’ Scientific Society, Department of Ophthalmology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
https://orcid.org/0009-0009-7799-7252
Dominika Hennik
Students’ Scientific Society, Department of Ophthalmology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
https://orcid.org/0009-0001-5270-3440
Sebastian Sirek
1. Department of Ophthalmology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland 2. Ophthalmology Clinic, Department of Ophthalmology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
https://orcid.org/0000-0002-3138-3011
Dorota Wyględowska-Promieńska
1. Department of Ophthalmology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland 2. Ophthalmology Clinic, Department of Ophthalmology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
https://orcid.org/0000-0001-5336-3460

Abstract

Central serous chorioretinopathy is a retinal disorder marked by subretinal fluid leakage causing visual impairment, image distortion, and color perception changes. Despite its prevalence, managing chronic central serous chorioretinopathy is challenging due to its complex pathogenesis and recurrent nature. Treatment options include mineralocorticoid receptor antagonists, carbonic anhydrase inhibitors, photodynamic therapy, and subthreshold micropulse laser. This review evaluates current therapies in terms of safety and efficacy and explores emerging strategies for improved management.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Marcinkowski K, Michalik M, Hennik D, Sirek S, Wyględowska-Promieńska D. Central serous chorioretinopathy management: current evidence and future directions in pharmacologic and phototherapeutic interventions – a literature review. Ophthatherapy [Internet]. 2026Mar.24 [cited 2026May30];13(1):A0005. Available from: https://www.journalsmededu.pl/index.php/ophthatherapy/article/view/3274
Issue
Vol 13 No 1 (2026)
Section
Conservative treatment
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. van Rijssen TJ, van Dijk EHC, Yzer S et al. Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019; 73: 100770. https://doi.org/10.1016/j.preteyeres.2019.07.003.
2. Von Graefe A. Ueber centrale recidivierende retinitis. Graefes Arch Clin Exp Ophthalmol. 1866; 12(12): 211-5.
3. Kitzmann AS, Pulido JS, Diehl NN et al. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology. 2008; 115(1): 169-73. https://doi.org/10.1016/j.ophtha.2007.02.032.
4. Gäckle HC, Lang GE, Freissler KA et al. Chorioretinopathia centralis serosa. Klinische, fluoreszeinangiographische und demographische Aspekte [Central serous chorioretinopathy. Clinical, fluorescein angiography and demographic aspects]. Ophthalmologe. 1998; 95(8): 529-33. https://doi.org/10.1007/s003470050310.
5. Levine R, Brucker AJ, Robinson F. Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography. Ophthalmology. 1989; 96(6): 854-9.
6. Semeraro F, Morescalchi F, Russo A et al. Central Serous Chorioretinopathy: Pathogenesis and Management. Clin Ophthalmol. 2019; 13: 2341-52. https://doi.org/10.2147/OPTH.S220845.
7. Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol. 1967; 63(3): 1-139.
8. Mrejen S, Balaratnasingam C, Kaden TR et al. Long-term Visual Outcomes and Causes of Vision Loss in Chronic Central Serous Chorioretinopathy. Ophthalmology. 2019; 126(4): 576-88. https://doi.org/10.1016/j.ophtha.2018.12.048.
9. Singh SR, Matet A, van Dijk EHC et al. Discrepancy in current central serous chorioretinopathy classification. Br J Ophthalmol. 2019; 103(6): 737-42. https://doi.org/10.1136/bjophthalmol-2018-312435.
10. Gawęcki M, Grzybowski A, Pompein-Batkiewicz M. Significant Visual Impairment after Short-Lasting Central Serous Chorioretinopathy. Case Rep Ophthalmol. 2022; 13(3): 678-85. https://doi.org/10.1159/000525924.
11. Breukink MB, Dingemans AJ, den Hollander AI et al. Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life. Clin Ophthalmol. 2016; 11: 39-46. https://doi.org/10.2147/OPTH.S115685.
12. Daruich A, Matet A, Dirani A et al. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015; 48: 82-118. https://doi.org/10.1016/j.preteyeres.2015.05.003.
13. Liew G, Quin G, Gillies M et al. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol. 2013; 41(2): 201-14. https://doi.org/10.1111/j.1442-9071.2012.02848.x.
14. Türkcü FM, Şahin A, Bez Y et al. Vision-related quality of life in patients with chronic central serous chorioretinopathy. Semin Ophthalmol. 2015; 30(4): 272-75. https://doi.org/10.3109/08820538.2013.839818.
15. Haimovici R, Koh S, Gagnon DR et al. Central Serous Chorioretinopathy Case-Control Study Group. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology. 2004; 111(2): 244-9. https://doi.org/10.1016/j.ophtha.2003.09.024.
16. Tsai DC, Chen SJ, Huang CC et al. Risk of central serous chorioretinopathy in adult prescribed oral corticosteroids: a population-based study in Taiwan. Retina. 2014; 34(9): 1867-74. https://doi.org/10.1097/IAE.0000000000000159.
17. Nicholson BP, Atchison E, Idris AA et al. Central serous chorioretinopathy and glucocorticoids: an update on evidence for association. Surv Ophthalmol. 2018; 63(1): 1-8. https://doi.org/10.1016/j.survophthal.2017.06.008.
18. van Dijk EHC, Schellevis RL, Breukink MB et al. Familial central serous chorioretinopathy. Retina. 2019; 39(2): 398-407. https://doi.org/10.1097/IAE.0000000000001966.
19. Mohabati D, Schellevis RL, van Dijk EHC et al. Genetic risk factors in acute central serous chorioretinopathy. Retina. 2019; 39(12): 2303-10. https://doi.org/10.1097/IAE.0000000000002333.
20. Nudleman E, Witmer MT, Kiss S et al. Central serous chorioretinopathy in patients receiving exogenous testosterone therapy. Retina. 2014; 34(10): 2128-32. https://doi.org/10.1097/IAE.0000000000000198.
21. Conrad R, Geiser F, Kleiman A et al. Temperament and character personality profile and illness-related stress in central serous chorioretinopathy. ScientificWorldJournal. 2014; 2014: 631687. https://doi.org/10.1155/2014/631687.
22. Williams RB Jr, Lane JD, Kuhn CM et al. Type A behavior and elevated physiological and neuroendocrine responses to cognitive tasks. Science. 1982; 218(4571): 483-5. https://doi.org/10.1126/science.7123248.
23. Gungor Kobat S, Yusufoglu E, Gul FC et al. Plasma dopamine and catecholamine levels in patients with central serous chorioretinopathy. J Fr Ophtalmol. 2021; 44(5): 621-5. https://doi.org/10.1016/j.jfo.2020.08.032.
24. Mohabati D, Boon CJF, Hoyng CB et al. Fundus autofluorescence abnormalities can predict fluorescein angiography abnormalities in patients with chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2023; 261(9): 2489-95. https://doi.org/10.1007/s00417-023-06042-z.
25. Kaye R, Chandra S, Sheth J et al. Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities. Prog Retin Eye Res. 2020; 79: 100865. https://doi.org/10.1016/j.preteyeres.2020.100865.
26. Pujari A, Surve A, Azad SV et al. Optical coherence tomography angiography in central serous chorioretinopathy: The current clinical role and future perspectives. Surv Ophthalmol. 2022; 67(1): 68-82. https://doi.org/10.1016/j.survophthal.2021.05.003.
27. Ficker L, Vafidis G, While A et al. Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol. 1988; 72(11): 829-34. https://doi.org/10.1136/bjo.72.11.829.
28. Sun Z, Huang Y, Nie C et al. Efficacy and safety of subthreshold micropulse laser compared with threshold conventional laser in central serous chorioretinopathy. Eye (Lond). 2020; 34(9): 1592-9. https://doi.org/10.1038/s41433-019-0692-8.
29. Gülkaş S, Şahin Ö. Current therapeutic approaches to chronic central serous chorioretinopathy Turk J Ophthalmol. 2019; 49(1): 30-9. https://doi.org/10.4274/tjo.galenos.2018.49035.
30. Sorrentino T, Allegrini D, De Rosa G et al. Settings and clinical applications of subthreshold micropulse laser therapy: A Review. J Clin Med. 2024; 13(19): 5729. https://doi.org/10.3390/jcm13195729.
31. Luttrull JK, Dorin G. Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review. Curr Diabetes Rev. 2012; 8(4): 274-84.
32. Mainster MA. Decreasing retinal photocoagulation damage: principles and techniques. Semin Ophthalmol. 1999; 14(4): 200-9.
33. Novak MA, Singerman LJ, Rice TA. Krypton and argon laser photocoagulation for central serous chorioretinopathy. Retina. 1987; 7(3): 162-9.
34. van Dijk EHC, Feenstra HMA, Bjerager J et al. Comparative efficacy of treatments for chronic central serous chorioretinopathy: A systematic review with network meta-analyses. Acta Ophthalmol. 2023; 101(2): 140-59. https://doi.org/10.1111/aos.15263.
35. Daniell MD, Hill JS. A history of photodynamic therapy. Aust N Z J Surg. 1991; 61(5): 340-8. https://doi.org/10.1111/j.1445-2197.1991.tb00230.x .
36. Zhang X, Lim CZF, Chhablani J et al. Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies. Eye Vis (Lond). 2023; 10(1): 33. https://doi.org/10.1186/s40662-023-00349-y.
37. Shin JY, Woo SJ, Yu HG et al. Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2011; 31(1): 119-26. https://doi.org/10.1097/IAE.0b013e3181e378f2.
38. Feenstra HMA, Diederen RMH, Lamme MJCM et al. Increasing evidence for the safety of fovea-involving half-dose photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2023; 43(3): 379-88. https://doi.org/10.1097/IAE.0000000000003686.
39. Hua L, Lin B, Hong J et al. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy. Eur Rev Med Pharmacol Sci. 2018; 22(2): 278-84. https://doi.org/10.26355/eurrev_201801_14169.
40. Zhao M, Zhang F, Chen Y et al. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial. JAMA Ophthalmol. 2015; 133(3): 333-40. https://doi.org/10.1001/jamaophthalmol.2014.5312.
41. > Kumashiro S, Takagi S, Itokawa T et al. Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. BMC Ophthalmol. 2021; 21(1): 241. https://doi.org/10.1186/s12886-021-01980-w 42. Haga F, Maruko R, Sato C et al. Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: A 3-year follow-up study. PLoS One. 2017; 12(7): e0181479. https://doi.org/10.1371/journal.pone.0181479.
43. Katz G, Gur E, Moisseiev J et al. Early versus delayed photodynamic therapy for chronic central serous chorioretinopathy. Int Ophthalmol. 2023; 43(11): 4055-65. https://doi.org/10.1007/s10792-023-02822-y.
44. van Dijk EHC, Fauser S, Breukink MB et al. Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial. Ophthalmology. 2018; 125(10): 1547-55. https://doi.org/10.1016/j.ophtha.2018.04.021.
45. Chan WM, Lam DS, Lai TY et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003; 87(12): 1453-8. https://doi.org/10.1136/bjo.87.12.1453.
46. van Dijk EHC, Dijkman G, Theelen T et al. Short-term findings on optical coherence tomography and microperimetry in chronic central serous chorioretinopathy patients treated with half-dose photodynamic therapy. Retin Cases Brief Rep. 2018;12(4):266-271. https://doi.org/10.1097/ICB.0000000000000498.
47. Tzekov R, Lin T, Zhang KM et al. Ocular changes after photodynamic therapy. Invest Ophthalmol Vis Sci. 2006; 47(1): 377-85. https://doi.org/10.1167/iovs.05-0838.
48. Lee PY, Kim KS, Lee WK. Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy. Jpn J Ophthalmol. 2009; 53(1): 52-6. https://doi.org/10.1007/s10384-008-0613-z.
49. Silva RM, Ruiz-Moreno JM, Gomez-Ulla F et al. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study. Retina. 2013; 33(2): 309-15. https://doi.org/10.1097/IAE.0b013e3182670fbe.
50. van Dijk EHC, van Rijssen TJ, Subhi Y, Boon CJF. Photodynamic Therapy for Chorioretinal Diseases: A Practical Approach. Ophthalmol Ther. 2020; 9(2): 329-42. https://doi.org/10.1007/s40123-020-00250-0.
51. Sirks MJ, Subhi Y, Rosenberg N et al. Perspectives and Update on the Global Shortage of Verteporfin (Visudyne®). Ophthalmol Ther. 2024; 13(7): 1821-31. https://doi.org/10.1007/s40123-024-00952-9.
52. Oribio-Quinto C, Fernández-Vigo JI, Bilbao-Malavé V et al. Anatomical and functional impact of verteporfin shortage in patients with chronic central serous chorioretinopathy. Photodiagnosis Photodyn Ther. 2023; 42: 103501. https://doi.org/10.1016/j.pdpdt.2023.103501.
53. Servillo A, Sacconi R, Zucchiatti I et al. No-dose photodynamic therapy against halfdose photodynamic therapy for treatment of central serous chorioretinopathy. Ophthalmol Ther. 2023; 12(4): 2199-208. https://doi.org/10.1007/s40123-023-00739-4.
54. Scholz P, Altay L, Fauser S. A Review of Subthreshold Micropulse Laser for Treatment of Macular Disorders. Adv Ther. 2017; 34(7): 1528-55. https://doi.org/10.1007/s12325-017-0559-y .
55. Midena E, Bini S, Martini F et al. Changes of aqueous humor müller cells’ biomarkers in human patients affected by diabetic macular edema after subthreshold micropulse laser treatment. Retina. 2020; 40(1): 126-34. https://doi.org/10.1097/IAE.0000000000002356.
56. Mansouri A, Sampat KM, Malik KJ et al. Efficacy of subthreshold micropulse laser in the treatment of diabetic macular edema is influenced by pre-treatment central foveal thickness. Eye (Lond). 2014; 28(12): 1418-24. https://doi.org/10.1038/eye.2014.264.
57. Breukink MB, Mohr JK, Ossewaarde-van Norel A et al. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol. Acta Ophthalmol. 2016; 94(2): 187-97. https://doi.org/10.1111/aos.12938.
58. Ambiya V, Goud A, Mathai A et al. Microsecond yellow laser for subfoveal leaks in central serous chorioretinopathy. Clin Ophthalmol. 2016; 10: 1513-9. https://doi.org/10.2147/OPTH.S112431.
59. Joondeph BC, Joondeph HC, Blair NP. Retinal macroaneurysms treated with the yellow dye laser. Retina. 1989; 9(3): 187-92.
60. Moorman CM, Hamilton AM. Clinical applications of the MicroPulse diode laser. Eye (Lond). 1999; 13(Pt 2): 145-50. https://doi.org/10.1038/eye.1999.41.
61. Behnia M, Khabazkhoob M, Aliakbari S et al. Improvement in visual acuity and contrast sensitivity in patients with central serous chorioretinopathy after macular subthreshold laser therapy. Retina. 2013; 33(2): 324-8. https://doi.org/10.1097/IAE.0b013e3182670fa3.
62. Kang S, Park YG, Kim JR et al. Selective Retina Therapy in Patients With Chronic Central Serous Chorioretinopathy: A Pilot Study. Medicine (Baltimore). 2016; 95(3): e2524. https://doi.org/10.1097/MD.0000000000002524.
63. Li X, Long H, Hu Q. Efficacy of subthreshold micropulse laser for chronic central serous chorioretinopathy: A meta-analysis. Photodiagnosis Photodyn Ther. 2022; 39: 102931. https://doi.org/10.1016/j.pdpdt.2022.102931.
64. Wood EH, Karth PA, Sanislo SR, Moshfeghi DM, Palanker DV. Non-damaging retinal laser therapy for treatment of central serous chorioretinopathy: What is the Evidence?. Retina. 2017; 37(6): 1021-33. https://doi.org/10.1097/IAE.0000000000001386.
65. Jeon SH, Kim M, Roh YJ. Use of a fundus image-based titration strategy for selective retina therapy for central serous chorioretinopathy. J Clin Med. 2024; 13(17): 5230. https://doi.org/10.3390/jcm13175230.
66. Parthasarathy HK, Ménard J, White WB et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011; 29(5): 980-90. https://doi.org/10.1097/HJH.0b013e3283455ca5.
67. Zannad F, McMurray JJ, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364(1): 11-21. https://doi.org/10.1056/NEJMoa1009492.
68. Zhao M, Célérier I, Bousquet E et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012; 122(7): 2672-9. https://doi.org/10.1172/JCI61427.
69. Pichi F, Carrai P, Ciardella A et al.; Central Serous Chorioretinopathy Study Group. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol. 2017; 37(5): 1115-25. https://doi.org/10.1007/s10792-016-0377-2.
70. Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int. 2000; 57(4): 1408-11. https://doi.org/10.1046/j.1523-1755.2000.00983.x .
71. Danjuma MI, Mukherjee I, Makaronidis J et al. Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. Curr Hypertens Rep. 2014; 16(2): 414. https://doi.org/10.1007/s11906-013-0414-8.
72. Bousquet E, Beydoun T, Zhao M et al. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2013; 33(10): 2096-102. https://doi.org/10.1097/IAE.0b013e318297a07a.
73. Rahimy E, Pitcher JD 3rd, Hsu J et al. A randomized double-blind placebo-control pilot study of eplerenone for the treatment of central serous chorioretinopathy (ECSELSIOR). Retina. 2018; 38(5): 962-9. https://doi.org/10.1097/IAE.0000000000001649.
74. Lee JH, Lee SC, Kim H et al. Comparison of short-term efficacy between oral spironolactone treatment and photodynamic therapy for the treatment of non-resolving central serous chorioretinopathy. Retina. 2019; 39(1): 127-33. https://doi.org/10.1097/IAE.0000000000001913.
75. Wang SK, Sun P, Tandias RM et al. Mineralocorticoid receptor antagonists in central serous chorioretinopathy: a meta-analysis of randomized controlled trials. Ophthalmol Retina. 2019; 3(2): 154-60. https://doi.org/10.1016/j.oret.2018.09.003.
76. Lotery A, Sivaprasad S, O’Connell A et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020; 395(10220): 294-303. https://doi.org/10.1016/S0140-6736(19)32981-2.
77. Schwartz R, Habot-Wilner Z, Martinez MR et al. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. Acta Ophthalmol. 2017; 95(7): e610-8. https://doi.org/10.1111/aos.13491.
78. Aslam S, Gupta V. Carbonic Anhydrase Inhibitors. In: StatPearls. StatPearls Publishing, Treasure Island (FL) 2023.
79. Cox SN, Hay E, Bird AC. Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol. 1988; 106(9): 1190-5. https://doi.org/10.1001/archopht.1988.01060140350030.
80. Pikkel J, Beiran I, Ophir A et al. Acetazolamide for central serous retinopathy. Ophthalmology. 2002; 109(9): 1723-5. https://doi.org/10.1016/s0161-6420(02)01157-0.
81. Kwak JH, Hong SW, Ra H et al. Effect of Acetazolamide on Choroidal Morphology in Central Serous Chorioretinopathy. Korean J Ophthalmol. 2019; 33(6): 493-9. https://doi.org/10.3341/kjo.2019.0063.
82. Wuarin R, Kakkassery V, Consigli A et al. Combined Topical Anti-inflammatory and Oral Acetazolamide in the Treatment of Central Serous Chorioretinopathy. Optom Vis Sci. 2019; 96(7): 500-506 https://doi.org/10.1097/OPX.0000000000001394.
83. Liew G, Ho IV, Ong S et al. Efficacy of topical carbonic anhydrase inhibitors in reducing duration of chronic central serous chorioretinopathy. Transl Vis Sci Technol. 2020; 9(13): 6. https://doi.org/10.1167/tvst.9.13.6.
84. Muresan L, Cismaru G, Muresan C et al. Beta-blockers for the treatment of arrhythmias: bisoprolol – a systematic review. Ann Pharm Fr. 2022; 80(5): 617-34. https://doi.org/10.1016/j.pharma.2022.01.007.
85. Larochelle P, Tobe SW, Lacourcière Y. β-Blockers in hypertension: studies and metaanalyses over the years. Can J Cardiol. 2014; 30(5 Suppl): S16-22. https://doi.org/10.1016/j.cjca.2014.02.012.
86. Archer C, Wiles N, Kessler D et al. Beta-blockers for the treatment of anxiety disorders: A systematic review and meta-analysis. J Affect Disord. 2025; 368: 90-9. https://doi.org/10.1016/j.jad.2024.09.068.
87. Frambach DA, Fain GL, Farber DB et al. Beta adrenergic receptors on cultured human retinal pigment epithelium. Invest Ophthalmol Vis Sci. 1990; 31(9): 1767-72.
88. Oliver E, Mayor F Jr, D’Ocon P. Beta-blockers: Historical Perspective and Mechanisms of action. Rev Esp Cardiol (Engl Ed). 2019; 72(10): 853-62. https://doi.org/10.1016/j.rec.2019.04.006.
89. Gonçalves AN, Scott IU, Jorge R. Alternative management of central serous chorioretinopathy using intravitreal metoprolol. Int J Retina Vitreous. 2022; 8(1): 50. https://doi.org/10.1186/s40942-022-00400-5.
90. Chen LC, Ma JW, Shieh PC et al. Oral treatment of central serous chorioretinopathy patients using propranolol tablets. Pharmaceuticals (Basel). 2020; 13(11): 336. https://doi.org/10.3390/ph13110336.
91. Sandeep K, Venugopal KC, Javagal AP et al. Comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy. Indian J Ophthalmol. 2023; 71(10): 3381-5. https://doi.org/10.4103/IJO.IJO_169_23.
92. Chrapek O, Jirkova B, Kandrnal V et al. Treatment of central serous chorioretinopathy with beta-blocker metipranolol. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015; 159(1): 120-3. https://doi.org/10.5507/bp.2013.015.
93. Nicolò M, Desideri LF, Vagge A et al. Current Pharmacological Treatment Options for Central Serous Chorioretinopathy: A Review. Pharmaceuticals (Basel). 2020; 13(10): 264. https://doi.org/10.3390/ph13100264.
94. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol. 1999; 39: 1-17. https://doi.org/10.1146/annurev.pharmtox.39.1.1.
95. Chikaraishi Y, Matsunaga N, Shimazawa M et al. Rifampicin inhibits the retinal neovascularization in vitro and in vivo. Exp Eye Res. 2008; 86(1): 131-7. https://doi.org/10.1016/j.exer.2007.10.003.
96. Steinle NC, Gupta N, Yuan A et al. Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy. Br J Ophthalmol. 2012; 96(1): 10-3. https://doi.org/10.1136/bjophthalmol-2011-300183.
97. Mårde Arrhén Y, Nylén H, Lövgren-Sandblom A et al. A comparison of 4β-hydroxycholesterol : cholesterol and 6β-hydroxycortisol : cortisol as markers of CYP3A4 induction. Br J Clin Pharmacol. 2013; 75(6): 1536-40. https://doi.org/10.1111/bcp.12016.
98. Shulman S, Goldenberg D, Schwartz R et al. Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2016; 254(1): 15-22. https://doi.org/10.1007/s00417-015-2989-z.
99. Venkatesh R, Agarwal M, Kantha M. Efficacy of oral rifampicin in chronic central serous chorioretinopathy. Ther Adv Ophthalmol. 2018; 10: 2515841418807130. https://doi.org/10.1177/2515841418807130.
100. Nelson J, Saggau DD, Nielsen JS. Rifampin induced hepatotoxicity during treatment for chronic central serous chorioretinopathy. Retin Cases Brief Rep. 2014; 8(1): 70-2. https://doi.org/10.1097/ICB.0000000000000007.
101. Tostmann A, Boeree MJ, Aarnoutse RE et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008; 23(2): 192-202. https://doi.org/10.1111/j.1440-1746.2007.05207.x.
102. Westphal JF, Vetter D, Brogard JM. Hepatic side-effects of antibiotics. J Antimicrob Chemother. 1994; 33(3): 387-401. https://doi.org/10.1093/jac/33.3.387.
103. Beloor Suresh A, Rosani A, Patel P et al. Rifampin. In: StatPearls. StatPearls Publishing, Treasure Island (FL) 2023.
104. Bedoui Y, Guillot X, Sélambarom J et al. Methotrexate an Old Drug with New Tricks. Int J Mol Sci. 2019; 20(20): 5023. https://doi.org/10.3390/ijms20205023.
105. Kurup SK, Oliver A, Emanuelli A et al. Low-dose methotrexate for the treatment of chronic central serous chorioretinopathy: a retrospective analysis. Retina. 2012; 32(10): 2096-101. https://doi.org/10.1097/IAE.0b013e31825dd281.
106. Abrishami M, Mousavi M, Hosseini SM et al. Treatment of chronic central serous chorioretinopathy with oral methotrexate. J Ocul Pharmacol Ther. 2015; 31(8): 468-75. https://doi.org/10.1089/jop.2014.0173.
107. Torres-Soriano ME, García-Aguirre G, Kon-Jara V et al. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch Clin Exp Ophthalmol. 2008; 246(9): 1235-9. https://doi.org/10.1007/s00417-008-0856-x.
108. Song YY, Yu HY, Baek SK et al. Short-term effect of anti-VEGF for chronic central serous chorioretinopathy according to the presence of choroidal neovascularization using optical coherence tomography angiography. PLoS One. 2021; 16(1): e0245342. https://doi.org/10.1371/journal.pone.0245342.
109. You EL, Hébert M, Jin TS et al. Comparing interventions for chronic central serous chorioretinopathy: A network meta-analysis. Surv Ophthalmol. 2023; 68(4): 601-14. https://doi.org/10.1016/j.survophthal.2023.03.001.
110. Ji S, Wei Y, Chen J et al. Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: a meta-analysis. Int J Clin Pharm. 2017; 39(3): 514-21. https://doi.org/10.1007/s11096-017-0460-4.
111. Palakkamanil M, Munro M, Sethi A et al. Intravitreal anti-vascular endothelial growth factor for the treatment of chronic central serous retinopathy: a meta-analysis of the literature. BMJ Open Ophthalmol. 2023; 8(1): e001310. https://doi.org/10.1136/bmjophth-2023-001310.
112. Chung YR, Lee SJ, Song JH. Changes in the choroidal thickness following intravitreal bevacizumab injection in chronic central serous chorioretinopathy. J Clin Med. 2022; 11(12): 3375. https://doi.org/10.3390/jcm11123375.
113. Arora S, Surakiatchanukul T, Arora T et al. Sildenafil in ophthalmology: An update. Surv Ophthalmol. 2022; 67(2): 463-87. https://doi.org/10.1016/j.survophthal.2021.06.004.
114. Breazzano MP, Coleman DJ, Chen RWS et al. Prospective impact of sildenafil on chronic central serous chorioretinopathy: PISCES Trial. Ophthalmol Retina. 2020; 4(11): 1119-23. https://doi.org/10.1016/j.oret.2020.06.006.
115. Coleman DJ, Lee W, Daly S et al. Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil). Am J Ophthalmol Case Rep. 2020; 21: 100998. https://doi.org/10.1016/j.ajoc.2020.100998.
116. Finzi A, Valsecchi N, Tassi F et al. Chronic central serous chorioretinopathy with pigment epithelium detachment treated with sildenafil: a case report. Case Rep Ophthalmol. 2022; 13(3): 692-699. https://doi.org/10.1159/000524992.
117. Damar E, Toklu Y, Tuncel A et al. Does therapeutic dose of sildenafil citrate treatment lead to central serous chorioretinopathy in patients with erectile dysfunction?. Am J Mens Health. 2013; 7(5): 439-43. https://doi.org/10.1177/1557988313480808.
118. Fraunfelder FW, Fraunfelder FT. Central serous chorioretinopathy associated with sildenafil. Retina. 2008; 28(4): 606-9. https://doi.org/10.1097/IAE.0b013e31815ec2c8.
119. Gordon-Bennett P, Rimmer T. Central serous chorioretinopathy following oral tadalafil. Eye (Lond). 2012; 26(1): 168-9. https://doi.org/10.1038/eye.2011.250.
120. Mohammadpour M, Khodaparast M, Khorrami-Nejad M. Central serous chorioretinopathy following ingestion of sildenafil citrate. Clin Optom (Auckl). 2019; 11: 73-75. https://doi.org/10.2147/OPTO.S210877.
121. Anitua E, Muruzabal F, Tayebba A et al. Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies. Acta Ophthalmol. 2015; 93(8): e605-14. https://doi.org/10.1111/aos.12710.
122. Maziarz A, Kocan B, Bester M et al. How electromagnetic fields can influence adult stem cells: positive and negative impacts. Stem Cell Res Ther. 2016; 7(1): 54. https://doi.org/10.1186/s13287-016-0312-5.
123. Arslan U, Özmert E. Treatment of resistant chronic central serous chorioretinopathy via platelet-rich plasma with electromagnetic stimulation. Regen Med. 2020; 15(8): 2001-14. https://doi.org/10.2217/rme-2020-0056.